PositiveID Acquires MFSI to Bring Sample Prep, MDx Tech to Biodefense, Clinical Markets | GenomeWeb

By Ben Butkus

Medical technology firm PositiveID said last week that it will acquire Bay Area biological-detection and sample-prep technology developer MicroFluidic Systems for as much as $8.2 million.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: epigenetic contributors to type 1 diabetes, assembly algorithm to detect structural variations, and more.

The Financial Times looks into how sequencing is moving into the clinic.

Mitochondrial replacement therapy may soon be occurring in the UK, according to the Guardian.

The US House of Representatives has passed the latest version of the 21st Century Cures Act.